INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Scotiabank Analyst Says

INmune Bio (NASDAQ:INMB) had its price target boosted by equities researchers at Scotiabank from $22.00 to $23.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “sector outperform” rating on the stock. Scotiabank’s target price would suggest a potential upside of 151.92% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. RODMAN&RENSHAW upgraded INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Rodman & Renshaw began coverage on INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 target price on the stock. Finally, Alliance Global Partners initiated coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price target for the company. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $21.00.

INmune Bio Trading Up 10.7 %

INmune Bio stock opened at $9.13 on Tuesday. INmune Bio has a 12-month low of $4.32 and a 12-month high of $14.74. The firm has a market capitalization of $202.41 million, a price-to-earnings ratio of -4.19 and a beta of 1.87. The firm has a 50 day moving average of $6.44 and a 200 day moving average of $6.11.

Institutional Investors Weigh In On INmune Bio

Large investors have recently bought and sold shares of the business. Financial Advocates Investment Management grew its stake in shares of INmune Bio by 14.8% in the 4th quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after buying an additional 2,000 shares in the last quarter. Rhumbline Advisers increased its stake in INmune Bio by 16.9% during the fourth quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock worth $78,000 after acquiring an additional 2,424 shares during the last quarter. Fermata Advisors LLC lifted its stake in shares of INmune Bio by 10.0% in the 4th quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock valued at $219,000 after purchasing an additional 4,267 shares during the last quarter. LPL Financial LLC boosted its stake in INmune Bio by 33.0% during the fourth quarter. LPL Financial LLC now owns 19,072 shares of the company’s stock worth $89,000 after buying an additional 4,730 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock valued at $53,000 after purchasing an additional 5,461 shares during the last quarter. Institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.